Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 52-Week High - Here's What Happened

Key Points

• Swedish Orphan Biovitrum stock reached a new 52-week high of $33.30 during trading on Monday, significantly up from its previous close of $30.05.
• The company reported a net margin of 16.05% and earnings per share (EPS) of $0.24, exceeding analysts' expectations of $0.18 for the quarter.
• With a market cap of $11.85 billion and a price-to-earnings ratio of 27.98, Swedish Orphan Biovitrum operates in multiple therapeutic areas including haematology and immunology.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $33.30 and last traded at $33.30, with a volume of 173 shares trading hands. The stock had previously closed at $30.05.

Swedish Orphan Biovitrum Stock Performance

The stock's 50 day moving average price is $29.77 and its 200 day moving average price is $29.49. The company has a current ratio of 1.00, a quick ratio of 0.66 and a debt-to-equity ratio of 0.22. The company has a market cap of $11.85 billion, a price-to-earnings ratio of 27.98 and a beta of 0.49.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.06. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%. The company had revenue of $649.61 million during the quarter, compared to the consensus estimate of $644.68 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.